Horizons ETFs Management (Canada) Inc. recently announced completion of its quarterly rebalance of the constituent holdings of the Horizons Marijuana Life Sciences Index ETF (“HMMJ”). Pre-clinical stage biopharmaceutical company InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) is one of 11 new holdings that have been added to HMMJ’s portfolio, which is the world’s first ETF offering direct exposure to North American-listed securities involved with marijuana bioengineering and production. “Cannabis has been one of the newest and fastest-growing asset classes of 2017, presently valued at approximately $23 billion,” Steve Hawkins, president and CEO of Horizons ETFs, stated in a news release. “The continued expansion of HMMJ’s Index and portfolio demonstrates how quickly this sector has evolved and why it should be considered a long-term, domestic investment opportunity for Canadian investors.”
To view the full press release, visit http://cnw.fm/bXm5e
About InMed
InMed is a preclinical stage biopharmaceutical company specializing in the research and development of novel, cannabinoid-based prescription drug therapies utilizing novel drug delivery systems. InMed conducts research, discovery, preclinical, clinical, regulatory, manufacturing and commercial development activities for its product candidates. InMed’s proprietary bioinformatics database assessment tool, the biosynthesis manufacturing process and its drug development programs are the fundamental value drivers of the company. For more information, visit www.InMedPharma.com
More from CannabisNewsBreaks
About CBDWire
CBDWire (CBDW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CBDNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CBDW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CBDW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CBDW brings its clients unparalleled visibility, recognition and brand awareness. CBDW is where news, content and information converge.
For more information please visit https://www.cbdwire.com
Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer
CBDWire (CBDW)
Denver, Colorado
cbdwire.com
303.498.7722 Office
Editor@CBDWire.com